H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational program for the treatment of endogenous Cushing’s syndrome, a severe and rare endocrine disorder characterized by chronic overproduction of cortisol.
The FDA’s regulatory decision follows the European Commission’s recent granting of Orphan Designation for the program, providing critical transatlantic regulatory momentum as the asset advances through clinical development.
Endogenous Cushing’s syndrome is associated with substantial systemic morbidity and elevated mortality, often leading to severe metabolic dysfunction, cardiovascular complications, cognitive impairments, and compromised quality of life. Current clinical management strategies remain constrained by limited pharmacological alternatives and high treatment-related burdens, highlighting an urgent unmet medical need for targeted therapeutics.
The FDA Orphan Drug Designation program provides key development incentives for promising therapies addressing rare diseases affecting fewer than 200,000 individuals in the United States. These benefits include tax credits for qualified clinical testing, exemptions from certain prescription drug user fees, and the potential for seven years of market exclusivity upon regulatory approval.
This dual regulatory recognition reinforces Lundbeck’s commitment to expanding its research and development pipeline into rare and specialized disease areas with high unmet needs, advancing innovative targeted therapies designed to alleviate the burden of debilitating chronic disorders worldwide.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
